UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

First-in-Man Clinical Trial of the Oral Pan-AKT Inhibitor MK-2206 in Patients With Advanced Solid Tumors

Journal of clinical oncology, 2011-12, Vol.29 (35), p.4688-4695

2011

Volltextzugriff (PDF)

Antibody drug conjugates: The dos and don'ts in clinical development

Pharmacology & therapeutics (Oxford), 2022-12, Vol.240, p.108235, Article 108235

Tolcher, Anthony W.

2022

Volltextzugriff (PDF)

Phase I, Pharmacokinetic, and Pharmacodynamic Study of AMG 479, a Fully Human Monoclonal Antibody to Insulin-Like Growth Factor Receptor 1

Journal of clinical oncology, 2009-12, Vol.27 (34), p.5800-5807

2009

Volltextzugriff (PDF)

A phase 1 dose-escalation and expansion study of binimetinib (MEK162), a potent and selective oral MEK1/2 inhibitor

British journal of cancer, 2017-02, Vol.116 (5), p.575-583

2017

Volltextzugriff (PDF)

Phase I Study of RO4929097, a Gamma Secretase Inhibitor of Notch Signaling, in Patients With Refractory Metastatic or Locally Advanced Solid Tumors

Journal of clinical oncology, 2012-07, Vol.30 (19), p.2348-2353

2012

Volltextzugriff (PDF)

Phase II Study of the Mammalian Target of Rapamycin Inhibitor Ridaforolimus in Patients With Advanced Bone and Soft Tissue Sarcomas

Journal of clinical oncology, 2012-01, Vol.30 (1), p.78-84

2012

Volltextzugriff (PDF)

Antitumor activity in RAS-driven tumors by blocking AKT and MEK

Clinical cancer research, 2015-02, Vol.21 (4), p.739-748

2015

Volltextzugriff (PDF)

Phase I and Pharmacokinetic Study of XRP6258 (RPR 116258A), a Novel Taxane, Administered as a 1-Hour Infusion Every 3 Weeks in Patients with Advanced Solid Tumors

Clinical cancer research, 2009-01, Vol.15 (2), p.723-730

2009

Volltextzugriff (PDF)

Phase I and Pharmacokinetic Study of YM155, a Small-Molecule Inhibitor of Survivin

Journal of clinical oncology, 2008-11, Vol.26 (32), p.5198-5203

2008

Volltextzugriff (PDF)

Phase I Pharmacokinetic and Biologic Correlative Study of Mapatumumab, a Fully Human Monoclonal Antibody With Agonist Activity to Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand Receptor-1

Journal of clinical oncology, 2007-04, Vol.25 (11), p.1390-1395

2007

Volltextzugriff (PDF)

Phase I Trial of the Novel Mammalian Target of Rapamycin Inhibitor Deforolimus (AP23573; MK-8669) Administered Intravenously Daily for 5 Days Every 2 Weeks to Patients With Advanced Malignancies

Journal of clinical oncology, 2008-01, Vol.26 (3), p.361-367

2008

Volltextzugriff (PDF)

Phase 1 first-in-human study of dalutrafusp alfa, an anti–CD73-TGF-β-trap bifunctional antibody, in patients with advanced solid tumors

Journal for immunotherapy of cancer, 2023-02, Vol.11 (2), p.e005267

2023

Volltextzugriff (PDF)

Phase I and Pharmacokinetic Study of CT-322 (BMS-844203), a Targeted Adnectin Inhibitor of VEGFR-2 Based on a Domain of Human Fibronectin

Clinical cancer research, 2011-01, Vol.17 (2), p.363-371

2011

Volltextzugriff (PDF)

Technology Insight: cytotoxic drug immunoconjugates for cancer therapy

Nature clinical practice. Oncology, 2007-04, Vol.4 (4), p.245-255

2007

Volltextzugriff (PDF)

Rational Approaches for Combination Therapy Strategies Targeting the MAP Kinase Pathway in Solid Tumors

Molecular cancer therapeutics, 2018-01, Vol.17 (1), p.3-16

2018

Volltextzugriff (PDF)

Dose and Schedule Study of Panitumumab Monotherapy in Patients with Advanced Solid Malignancies

Clinical cancer research, 2008-01, Vol.14 (2), p.502-508

2008

Volltextzugriff (PDF)

Phase I Study of Pembrolizumab (MK-3475; Anti-PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors

Clinical cancer research, 2015-10, Vol.21 (19), p.4286-4293

2015

Volltextzugriff (PDF)

Improving combination cancer therapy: the CombiPlex ® development platform

Future oncology (London, England), 2018-06, Vol.14 (13), p.1317-1332

2018

Volltextzugriff (PDF)

A Phase II, Pharmacokinetic, and Biological Correlative Study of Oblimersen Sodium and Docetaxel in Patients with Hormone-Refractory Prostate Cancer

Clinical cancer research, 2005-05, Vol.11 (10), p.3854-3861

2005

Volltextzugriff (PDF)

First-in-Human Study of AMG 820, a Monoclonal Anti-Colony-Stimulating Factor 1 Receptor Antibody, in Patients with Advanced Solid Tumors

Clinical cancer research, 2017-10, Vol.23 (19), p.5703-5710

2017

Volltextzugriff (PDF)

Phase Ib Study of Utomilumab (PF-05082566), a 4-1BB/CD137 Agonist, in Combination with Pembrolizumab (MK-3475) in Patients with Advanced Solid Tumors

Clinical cancer research, 2017-09, Vol.23 (18), p.5349-5357

2017

Volltextzugriff (PDF)

First-in-Human, Phase I Dose-Escalation and Dose-Expansion Study of Trophoblast Cell-Surface Antigen 2-Directed Antibody-Drug Conjugate Datopotamab Deruxtecan in Non-Small-Cell Lung Cancer: TROPION-PanTumor01

Journal of clinical oncology, 2023-10, Vol.41 (29), p.4678-4687

2023

Volltextzugriff (PDF)

The Clinical Effect of the Dual-Targeting Strategy Involving PI3K/AKT/mTOR and RAS/MEK/ERK Pathways in Patients with Advanced Cancer

Clinical cancer research, 2012-04, Vol.18 (8), p.2316-2325

2012

Volltextzugriff (PDF)

1 – 25 von 350

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(345)
Mit Volltextzugriff
(317)

Publikationsform

Artikel
(349)
Tagungsberichte
(1)

Sprache

Englisch
(350)
Japanisch
(1)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

First-in-Man Clinical Trial of the Oral Pan-AKT Inhibitor MK-2206 in Patients With Advanced Solid Tumors

Antibody drug conjugates: The dos and don'ts in clinical development

Phase I, Pharmacokinetic, and Pharmacodynamic Study of AMG 479, a Fully Human Monoclonal Antibody to Insulin-Like Growth Factor Receptor 1

A phase 1 dose-escalation and expansion study of binimetinib (MEK162), a potent and selective oral MEK1/2 inhibitor

Phase I Study of RO4929097, a Gamma Secretase Inhibitor of Notch Signaling, in Patients With Refractory Metastatic or Locally Advanced Solid Tumors

Phase II Study of the Mammalian Target of Rapamycin Inhibitor Ridaforolimus in Patients With Advanced Bone and Soft Tissue Sarcomas

Antitumor activity in RAS-driven tumors by blocking AKT and MEK

Phase I and Pharmacokinetic Study of XRP6258 (RPR 116258A), a Novel Taxane, Administered as a 1-Hour Infusion Every 3 Weeks in Patients with Advanced Solid Tumors

Phase I and Pharmacokinetic Study of YM155, a Small-Molecule Inhibitor of Survivin

Phase I Pharmacokinetic and Biologic Correlative Study of Mapatumumab, a Fully Human Monoclonal Antibody With Agonist Activity to Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand Receptor-1

Phase I Trial of the Novel Mammalian Target of Rapamycin Inhibitor Deforolimus (AP23573; MK-8669) Administered Intravenously Daily for 5 Days Every 2 Weeks to Patients With Advanced Malignancies

Ombrabulin plus cisplatin versus placebo plus cisplatin in patients with advanced soft-tissue sarcomas after failure of anthracycline and ifosfamide chemotherapy: a randomised, double-blind, placebo-controlled, phase 3 trial

Phase 1 first-in-human study of dalutrafusp alfa, an anti–CD73-TGF-β-trap bifunctional antibody, in patients with advanced solid tumors

Phase I and Pharmacokinetic Study of CT-322 (BMS-844203), a Targeted Adnectin Inhibitor of VEGFR-2 Based on a Domain of Human Fibronectin

Technology Insight: cytotoxic drug immunoconjugates for cancer therapy

Rational Approaches for Combination Therapy Strategies Targeting the MAP Kinase Pathway in Solid Tumors

Dose and Schedule Study of Panitumumab Monotherapy in Patients with Advanced Solid Malignancies

Phase I Study of Pembrolizumab (MK-3475; Anti-PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors

Improving combination cancer therapy: the CombiPlex ® development platform

A Phase II, Pharmacokinetic, and Biological Correlative Study of Oblimersen Sodium and Docetaxel in Patients with Hormone-Refractory Prostate Cancer

First-in-Human Study of AMG 820, a Monoclonal Anti-Colony-Stimulating Factor 1 Receptor Antibody, in Patients with Advanced Solid Tumors

Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Other Solid Tumors

Phase Ib Study of Utomilumab (PF-05082566), a 4-1BB/CD137 Agonist, in Combination with Pembrolizumab (MK-3475) in Patients with Advanced Solid Tumors

First-in-Human, Phase I Dose-Escalation and Dose-Expansion Study of Trophoblast Cell-Surface Antigen 2-Directed Antibody-Drug Conjugate Datopotamab Deruxtecan in Non-Small-Cell Lung Cancer: TROPION-PanTumor01

The Clinical Effect of the Dual-Targeting Strategy Involving PI3K/AKT/mTOR and RAS/MEK/ERK Pathways in Patients with Advanced Cancer

Suchergebnisse filtern